WARREN, N.J., June 11, 2020 /PRNewswire/ -- GlaxoSmithKline
(LSE/NYSE: GSK) announced that Voltaren Arthritis Pain Gel
(diclofenac sodium topical gel, 1% (NSAID) arthritis pain reliever)
recently became available over-the-counter (OTC) online and in
stores nationwide, providing the over 30 million1
osteoarthritis patients across the country broader access to a
leading pain relief option.
Experience the interactive Multichannel News Release here:
https://www.multivu.com/players/English/8731451-gsk-partners-with-paula-abdul-to-launch-voltaren-arthritis-pain-gel/
To launch the OTC offering, Voltaren is teaming up with music
superstar Paula Abdul, who uses
Voltaren for her arthritis pain. Staying active is important for
arthritis patients everywhere, and together, Voltaren and
Paula Abdul will inspire people to
"rediscover the joy of movement".
"I'm excited to partner with Voltaren Arthritis Pain Gel to
share my personal journey with arthritis and success using
Voltaren," Paula said. "I've put my joints through a lot over the
years. Dancing, jumping, flipping – it's my heart and soul, but
I've been pushing my joints to the limit for decades as a result.
When I was diagnosed with arthritis, my doctor prescribed Voltaren
which made a huge difference in relieving my pain and helping me
move with ease. I am so excited it's now available OTC at stores
nationwide."
Joint pain due to arthritis symptoms is a daily reality for
millions of people in the United
States, and with many people across the country staying at
home more often, finding arthritis pain relief is more important
than ever. In a recent study of 1,000 U.S. adults aged 35+
suffering from joint pain* conducted by Voltaren in partnership
with Wakefield Research, 82 percent of respondents said their
physical activity has decreased as a result of more time at home,
and 92 percent of respondents report that their joint pain is the
same or more severe during this time.
"Stay-at-home orders led to a unique set of challenges for those
with arthritis," said Jissan Cherian, Director, U.S. OTC
Marketing at GSK Consumer Healthcare. "Now, more than ever, we need
to offer solutions that help ease the challenge of joint pain and
inspire arthritis patients to rediscover the joy of movement, even
as we adapt to changing routines and a new way of life."
Additional results from the survey revealed:
- 78 percent of joint pain sufferers are finding ways to
incorporate new ways of moving into their routine since the start
of stay-at-home orders, including walking, stretching and stair
climbing
- With many changing their daily routines to adjust to the new
normal, 31 percent expressed they are unhappy about straying from
their usual pain management routine
- 54 percent have felt more knee pain due to walking around on
surfaces that offer less support
- 65 percent are looking for strategies to incorporate more
exercise in their households, like using soup cans as dumbbells, or
furniture as makeshift gym equipment
- More screen time on smartphones means increased finger pain
–nearly three in five joint pain sufferers age 35-55 report an
increase due to typing/holding devices while at home
- 51 percent are feeling joint pain due to new quarantine
activities, including bread kneading, knitting, gardening, DIY
projects, stretching and walking
Voltaren Gel, a doctor-prescribed arthritis treatment in the
U.S. for over 10 years with a proven safety profile, was approved
by the Food and Drug Administration (FDA) as an OTC treatment in
February, making it the first and only prescription strength,
nonsteroidal anti-inflammatory (NSAID) topical gel for arthritis
pain available OTC in the United
States. As an alternative to pills, Voltaren treats joint
pain by delivering medicine at the source, and is absorbed through
the skin and not through the stomach like most oral medicines.
Voltaren is applied directly to the site of pain, delivering
powerful arthritis pain relief. It is indicated for the treatment
of arthritis pain in the hand, wrist, elbow, foot, ankle or knee.
To date, millions of patients around the world have relied on
Voltaren as a powerful, well-tolerated and convenient therapeutic
alternative for treating arthritis pain.
"As the world leader in pain relief, we have seen how Voltaren
has helped people with osteoarthritis treat their pain and improve
their quality of life" Cherian said. "The OTC availability of
Voltaren Arthritis Pain helps to provide greater access to an
effective topical treatment option for joint pain patients, so more
people with osteoarthritis pain can find relief."
Voltaren Arthritis Pain Gel is now available online and at most
major retailers nationwide.
About Voltaren Arthritis Pain Gel
The active
ingredient in Voltaren Arthritis Pain Gel, diclofenac sodium, is an
effective medicine that is clinically proven to relieve joint pain
due to arthritis. Voltaren penetrates through the skin at the
application site to deliver arthritis pain relief. Voltaren offers
consumers who suffer from OA a well-tolerated alternative to oral
analgesics. For more information,
visit https://www.VoltarenGel.com/.
About osteoarthritis
Osteoarthritis (OA) is the most
common form of arthritis. OA occurs when the cartilage between
joints begins to break down and wear away, resulting in joint pain
and stiffness. OA occurs more frequently with age, and the pain can
gradually worsen over time. The most common symptoms associated
with OA include joint pain, stiffness, and decreased range of
motion.
GSK's commitment to pain relief
We are the world
leader in pain relief. With a portfolio of (systemic and topical)
products to relieve pain, our range brings comfort and ease to
millions. World-leading brands including Advil, Panadol and
Voltaren; and beloved local brands like Excedrin in the US and
Fenbid in China help people manage
their symptoms so they can enjoy life to the fullest.
Important safety information about Voltaren Arthritis
Pain
Before using the product, consumers should read the
Voltaren Arthritis Pain Gel Drug Facts Label.
* Methodological Notes
The GSK Voltaren Survey was
conducted by Wakefield Research (www.wakefieldresearch.com) between
May 7th and May 15th, 2020, among 1,000 US adults
ages 35+ suffering from joint pain, plus an additional oversample
of 500 joint pain sufferers in each of three states: Georgia, Oklahoma, Louisiana, using an email invitation and an
online survey.
Results of any sample are subject to sampling variation. The
magnitude of the variation is measurable and is affected by the
number of interviews and the level of the percentages expressing
the results. For the interviews conducted in this particular study,
the chances are 95 in 100 that a survey result does not vary, plus
or minus, by more than 3.1 percentage points from the result that
would be obtained if the interviews had been conducted with all
persons in the universe represented by the sample.
About GSK
GSK is a science-led global healthcare
company with a special purpose: to help people do more, feel
better, live longer. For further information please visit
www.gsk.com.
About GSK Consumer Healthcare
We are the world's
largest Consumer Healthcare company following our new joint venture
with Pfizer Consumer Healthcare. We develop and market a portfolio
of consumer-preferred and expert-recommended brands including
Sensodyne, parodontax, Poligrip, Advil, Centrum and Theraflu.
Media
Inquiries:
|
|
|
|
|
|
|
|
GSK Consumer
Healthcare
|
Caitlin
Kormann
|
+1 617 448
0557
|
(Warren)
|
Edelman
|
Jessica
Moschella
|
+1 201 953
1547
|
(New York
City)
|
|
|
|
|
1 https://www.cdc.gov/arthritis/basics/osteoarthritis.htm
View original
content:http://www.prnewswire.com/news-releases/gsk-consumer-healthcare-teams-up-with-paula-abdul-for-the-launch-of-voltaren-arthritis-pain-gel-301074754.html
SOURCE GSK Consumer Healthcare